We found no differences between non-survivors and survivors regarding sex, age of LT recipients, ABO blood type, Child-Pugh score, model for end-stage liver disease (MELD) score, Milan criteria, serum alpha-fetoprotein (AFP) levels, portal hypertension, number of nodules, size of nodules, tumor differentiation, infiltration, microvascular invasion, macrovascular invasion, pre-LT treatment or LT technique. This evidence concerns the gene AFP and liver disorder.